Related Experiment Video
Updated: Apr 2, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53
Published on: August 4, 2019
The Moving Target: Cis-Mutation-Driven Resistance to p53-Y220C Reactivator
Yanqing Liu1, Wei Gu1,2
1Institute for Cancer Genetics, Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York.
None:
The study by Fece de la Cruz, Varkaris, and colleagues uncovered a critical mechanism underlying resistance to the p53-Y220C reactivator rezatapopt in the PYNNACLE clinical trial. Specifically, rezatapopt treatment was shown to select for secondary mutations in the TP53 gene on the Y220C-mutant background, thereby abrogating its therapeutic efficacy. See related article by Fece de la Cruz et al., p. 677.
Related Concept Videos
Abnormal Proliferation
Treatment Resistant Cancers
Mismatch Repair
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
Mismatch Repair
Induced Pluripotent Stem Cells
Somatic...
DNA Damage can Stall the Cell Cycle

